Azole resistance - a growing concern
Treatment of aspergillosis, an infection of the sinus cavity or lungs caused by Aspergillus fumigatus
, has relied primarily on the azole class of drugs for successful clinical therapy. However, since the first case of azole-resistant aspergillosis was documented in 1999, the threat of these multidrug-resistant organisms continues to grow, with some strains now displaying resistance to newer azoles on the market, such as itraconazole. Aspergillosis is especially problematic for immunocompromised patients, in whom the infection is difficult to detect and treat with current methods, often resulting in high mortality.To aid researchers in the development and evaluation of new detection methods and drug therapies for aspergillosis, ATCC has put together a set of seven Aspergillus fumigatus
strains which display resistance to fluconazole, as well as varying levels of sensitivity to posaconazole, voriconazole, and itraconazole. The ATCC® Aspergillus fumigatus Drug Testing Panel (ATCC® MP-12™)
is a reliable tool consisting of fully-authenticated and characterized microbial strains that will provide researchers with consistent controls for reproducible assay results.
View drug testing profile
Looking for additional multidrug-resistant organisms?
ATCC houses a growing collection of bacterial and fungal strains to support on-going research to elucidate multidrug-resistance mechanisms, develop rapid detection methods, and evaluate novel antibiotics and therapeutics. Featured strains include Carbapenem-Resistant Enterobacteriaceae, Vancomycin Resistant Enterococci, Drug-Resistant Candida Albicans, and Methicillin-Resistant Staphylococcus aureus.